MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the first patients have been enrolled in the DURABILITY™ Iliac and VISIBILITY™ Iliac studies. Dr. Marc Bosiers, at AZ St-Blasius, Dendermonde, Belgium, enrolled the initial patients in the DURABILITY study, while Dr. Patrick Peeters, at Imelda Hospital, Bonheiden, Belgium, was responsible for the first enrollment in the VISIBILITY study.
